TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Ketamine in Adolescents With Treatment-Resistant Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female adolescents aged 12 to 18 years.~* Presence of recurrent major depression without psychotic features confirmed by the Kiddie-Schedule for Affective Disorders and Schizophrenia - Parent and Lifetime Version (Kaufman et al., 1997).~* Current depression severity measured by the Children's Depression Rating Scale (CDRS) (Poznanski, 1985) raw score greater than or equal to 36 at screening and the day ketamine is due to be received for the first time.~* Current depressive episode resistant to treatment, defined as failure to achieve remission (elimination of symptoms and restoration of pre-morbid psychosocial functioning) from at least 2 antidepressant trials of different pharmacological classes. Systematic evaluation of previous antidepressant trials will be assessed by using the Antidepressant Treatment History Form (Sackeim, 2001).~* If present, current antidepressant medication treatment must be dose stable for at least 2 months prior to beginning the study. (Patients will continue with current antidepressant treatment throughout the study. Based on our experience in current research at the VA Medical Center using serial ketamine for adult TRD, patients have shown positive results while continuing their current antidepressant treatment.)~Exclusion Criteria:~* Inability to speak English~* Inability or unwillingness to provide written informed consent~* A history of Mental Retardation or any Pervasive Developmental Disorder~* Current or lifetime diagnosis of schizophrenia, schizoaffective disorder, or psychosis Not Otherwise Specified.~* Family history with a first degree relative with schizophrenia, schizoaffective disorder, or psychosis Not Otherwise Specified.~* Diagnosis of seizures or other neurological disorders.~* Comorbid diagnosis of substance abuse or dependence, current or past.~* Clinically unstable medical illness.~* Current use of the following medications: any barbiturates, any narcotics, any non-benzodiazepine hypnotics at doses higher than zolpidem 10 mg qhs or equivalent for insomnia.~* For women: pregnancy (confirmed by baseline lab test).~* The presence of any MRI contra-indications such as MRI-incompatible metals in the body or claustrophobia.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- ketamine (Type: EXPERIMENTAL): Intravenous ketamine 0.5 mg/kg over 40 minutes will be given 6 times over 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Roflumilast in Patients With Asthma (BY217/M2-012)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Main Inclusion Criteria:~* Persistent bronchial asthma~* No change in asthma treatment within 4 weeks prior to visit 1~* Non-smoker or ex-smoker (for 12 months or longer)~Main Exclusion Criteria:~* Poorly controlled asthma or seasonal asthma~* History of lower airway infection four weeks prior to visit 1~* Chronic obstructive pulmonary disease (COPD) and/or other relevant lung disease~* Patients using \> 8-puffs/day-short-acting bronchodilator (beta-agonists) (more than 3 days per week on average) prior to visit 1~* Clinically relevant abnormal laboratory values suggesting an undiagnosed disease, severe renal insufficiency, active hepatitis or an HIV infection~* Diagnosis, treatment or remission of any cancer (other than basal cell carcinoma) within two years prior to visit 1~* Patients with chronic heart failure~* Suspected hypersensitivity and/or contraindication to roflumilast or albuterol/salbutamol~* Female patients of childbearing potential not using adequate means of birth control or pregnant or breast-feeding females~* Patients who have received any investigational medication or device in the month prior to visit 1 or who plan to use another investigational medication during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the exocrine pancreas~* Metastatic disease~* Documented disease progression after prior gemcitabine based therapy~* KPS \>/= 70~* Adequate bone marrow function~* Adequate hepatic function~* Adequate renal function~Exclusion Criteria:~* Active CNS metastasis~* Clinically significant GI disorders~* Severe arterial thromboembolic events less than 6 months before inclusion~* NYHA Class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled blood pressure~* Active infection or uncontrolled fever~* Pregnant or breast feeding patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MM-398 (Type: EXPERIMENTAL): MM-398 120 mg/m2 Q3W IV. Note: The published dose of ONIVYDE was expressed as the irinotecan hydrochloride trihydrate until October 2015. It is now expressed as the irinotecan free base. Converting a dose based on irinotecan hydrochloride trihydrate to a dose based on irinotecan free base is accomplished by substituting the Molecular Weight of irinotecan hydrochloride trihydrate (677.19 g/mole) with the Molecular Weight of irinotecan free base (586.68 g/mole), which results in a conversion factor of 0.866. 120 mg/m2 dose of irinotecan hydrochloride trihydrate is equivalent to 100 mg/ m2 of irinotecan free base.
- 5 Fluorouracil and Leucovorin IV (Type: ACTIVE_COMPARATOR): 5 Fluorouracil and Leucovorin IV
- MM-398, 5-FU and Leucovorin (Type: EXPERIMENTAL): MM-398 80 mg/m2, 5-FU and Leucovorin Q2W IV. Note: The published dose of ONIVYDE was expressed as the irinotecan hydrochloride trihydrate until October 2015. It is now expressed as the irinotecan free base. Converting a dose based on irinotecan hydrochloride trihydrate to a dose based on irinotecan free base is accomplished by substituting the Molecular Weight of irinotecan hydrochloride trihydrate (677.19 g/mole) with the Molecular Weight of irinotecan free base (586.68 g/mole), which results in a conversion factor of 0.866. 80 mg/m2 dose of irinotecan hydrochloride trihydrate is equivalent to 70 mg/ m2 of irinotecan free base.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ionis AGT-LRx in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have given written informed consent and be able to comply with all study requirements~* Healthy males or females aged 18-60 inclusive and weighing ≥ 50 kg at the time of Informed Consent~* Females must be non-pregnant and non-lactating, and either surgically sterile or post- menopausal~* Males must be surgically sterile, abstinent or using an acceptable contraceptive method~* BMI ≤ 35 kg/m~* Agree to conduct at home blood pressure monitoring (in triplicate using study provided device) every morning and every evening throughout study participation for Single-Dose Cohort subjects and every morning for Multiple-Dose Cohort subjects~Exclusion Criteria:~* Treatment with another Study Drug, biological agent, or device within one-month of Screening~* Subject with borderline orthostatic hypotension defined as a fall in systolic blood pressure of ≥ 17 mmHg or diastolic blood pressure of ≥ 7 mmHg when they assume a standing position (within 3 minutes of standing up)~* Use of nicotine-containing products or illicit drugs~* Considered unsuitable for inclusion by the Principal Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Ionis AGT-LRx (Type: EXPERIMENTAL): Ascending single and multiple doses of Ionis AGT-LRx administered subcutaneously.
- Placebo (Type: PLACEBO_COMPARATOR): Saline .9%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ivabradine on Top of Atenolol in Stable Angina Pectoris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Chronic stable angina pectoris~* Documented coronary artery disease~* Previous treatment with atenolol or other beta-blocker agent~* Exercise tolerance test positivity and stability~Exclusion Criteria:~* Heart rate \< 60 bpm~* Congestive heart failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Aspirin on REducing iNflammation in Human in Vivo Model of Acute Lung Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects~Exclusion Criteria:~* Age \< 18 years~* Pregnancy or breast feeding or woman of childbearing potential not using~* adequate contraception.~* Participation in a clinical trial of an investigational medicinal product within 30 days~* Consent declined Aspirin or non steroidal anti-inflammatory (NSAID) use in the past 4 weeks~* History of asthma~* Known aspirin or NSAID hypersensitivity~* History of peptic ulcer disease~* Platelet count \< 150 x 106/ml~* Aspirin resistance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Aspirin 75mg (Type: ACTIVE_COMPARATOR): Aspirin 75mg once daily for 7 days. Administered by mouth.
- Aspirin 1200mg (Type: ACTIVE_COMPARATOR): Asprin 600mg twice daily for 7 days. Administered by mouth.
- Lactose powder (Type: PLACEBO_COMPARATOR): Placebo for 7 days. Administered by mouth.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: COSOPT (Timolol/Dorzolamide Combination) Normal Tension Glaucoma Study (MK0507A-161)(COMPLETED)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have not been treated with a glaucoma medication within 6 weeks prior to study participation after diagnosis with primary open-angle glaucoma~* Patients with primary open-angle glaucoma based on gonioscopy~* Patients with normal tension glaucoma diagnosed based on accompanying optic disc cupping and reappearance of visual field defect corresponding to retinal nerve fiber layer defect.~* Subjects with \< 22 mm Hg of diurnal IOP measured using Goldmann applanation tonometer (every two hours between 9 a.m. and 5 p.m.)~Exclusion Criteria:~* Patients with another type of glaucoma but primary open-angle glaucoma~* Patients treated with other glaucoma medications within 6 weeks prior to study participation~* Patients with a history of chronic ocular inflammation or recurrent ocular inflammation~* Patients using contact lenses~* Patients who are allergic to timolol or dorzolamide~* Patients with a history of any of the following COSOPT (timolol/dorzolamide combination) contraindications:~  * Reactive airway diseases~ * Sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, cardiogenic shock~ * Severe renal impairment~* Patients with a history of significant ocular trauma or intraocular surgery within 6 months before participating the study, or intraocular laser surgery within 3 months before the participating the study~* Patients with a history of a corneal disease~* Patients who are using steroid or used the drug for more than 2 weeks within 12 months before participating the study~* Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Timolol/Dorzolamide (Type: EXPERIMENTAL): Timolol/Dorzolamide, 1 drop, twice daily, for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven Hodgkin lymphoma or primary mediastinal large B-cell lymphoma~* Patient should belong to any one of following clinical situations A.Patient who are not able to get autologous stem cell transplantation after relapsing the salvage chemotherapy B. Relapsed after autologous stem cell transplantation C. Refractory to salvage chemotherapy or autologous stem cell transplantation~* Adequate organ function as defined by the following criteria:~A. Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase (SGOT)) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase (SGPT)) ≤2.5 x local laboratory upper limit of normal (ULN), or AST and ALT less than or equal to 5 x ULN if liver function abnormalities are due to underlying malignancy B. Total serum bilirubin ≤1.5 x ULN C. Absolute neutrophil count (ANC) ≥ 1500/µL D. Platelets ≥ 100,000/µL E. Hemoglobin ≥ 9.0 g/dL (may be transfused or erythropoietin treated) F. Serum calcium ≤ 12.0 mg/dL G. Serum creatinine ≤ 1.5 x ULN~* At least one measurable lesion~* ECOG PS 0-2~* Informed consent~* Age from 19 to 80~Exclusion Criteria:~* Previously received allogeneic stem cell transplantation~* History of or known carcinomatous meningitis, or evidence of symptomatic leptomeningeal disease or secondary CNS involvement on CT or MRI scan.~* Currently uncontrolled active infection~* Previous history of recurrent herpes zoster or recurrent tuberculosis~* Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2.~* Pregnant or lactating females or patients who ar not willing to use an adequate method of birth control for the duration of the study

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib (Type: EXPERIMENTAL): 20 mg orally twice a day for 4 weeks (One cycle) Treatment continued until documented disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of Alagille Syndrome~2. Evidence of cholestasis~3. Moderate to severe pruritus~4. Ability to understand and willingness to sign informed consent/assent prior to initiation of any study procedures~Exclusion Criteria:~1. Surgical disruption of the enterohepatic circulation~2. Liver transplant~3. History or presence of other concomitant liver disease~4. Females who are pregnant or lactating~5. Known HIV infection

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- LUM001 (Type: EXPERIMENTAL): LUM001 for oral administration
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered orally once each day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Roflumilast and Cognition

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 35 years of age~* Healthy (i.e. absence of all exclusion criteria), normal static binocular acuity (corrected or uncorrected),~* Body mass index between 18.5 and 30~* Willingness to sign an informed consent.~* Positive evaluation on the memory screening~Exclusion Criteria:~* History of cardiac, hepatic, renal, pulmonary, neurological, gastrointestinal, haematological, or psychiatric illness~* First-degree relative with psychiatric disorder (in particular major depressive disorder and suicidality)~* Excessive drinking (\>20 glasses of alcohol containing beverages per week)~* Pregnancy or lactation~* Use of chronic medication other than oral contraceptives~* Use of recreational drugs in the 2 weeks preceding participation~* Smoking~* Orthostatic hypotension~* Lactose intolerance~* Sensory or motor deficits which could reasonably be expected to affect test performance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- roflumilast 100ug (Type: EXPERIMENTAL): None
- roflumilast 300ug (Type: EXPERIMENTAL): None
- roflumilast1000ug (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Ethinylestradiol/Dienogest in Random Start Rapid Endometrial Preparation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with endometrial polyps.~Exclusion Criteria:~* Patients with other endometrial pathologies.

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control (Type: NO_INTERVENTION): Patients with endometrial polyps undergone hysteroscopic polipectomy without endometrial preparation.
- Treatment (Type: EXPERIMENTAL): Patients with endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Ethinylestradiol/Dienogest 0.03mg/2mg at any time of the menstrual cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Brexpiprazole for Bipolar Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatient men and women ages 18-65~* Bipolar I or II disorders, currently depressed mood state based on a SCID for DSM-5; Mixed features in DSM-5 are allowed, but those with a Young Mania Rating Scale score ≥ 15 will be excluded~* Baseline MADRS score ≥ 20~Exclusion Criteria:~* Mood disorders other than bipolar I or II disorders (e.g., bipolar NOS, or cyclothymic disorders, schizophrenia, schizoaffective disorder, or unipolar depression based on the SCID), other disorders, e.g. anxiety disorders, will be allowed~* Current (last 14 days) treatment with an antipsychotic or antidepressant~* History of neuroleptic malignant syndrome or tardive dyskinesia~* Prior history of brexpiprazole use~* Vulnerable populations (e.g., pregnant, nursing, cognitively impaired, incarcerated)~* High risk for suicide defined as \> 1 attempt in past 12 months that required medical attention, any attempt in the past 3 months or current suicidal ideation with plan and intent such that outpatient care is precluded~* Severe or life-threatening medical condition, or laboratory or physical examination findings consistent with serious medical illness (e.g., dangerously abnormal electrolytes)~* Moderate or severe hepatic or renal impairment based on medical history and laboratory analyses~* Taking moderate or strong induces or inhibitors of CYP2D6 or CYP3A4

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Brexpiprazole (Type: EXPERIMENTAL): Brexipiprazole will be taken orally beginning at 0.5 mg/day with an increase to 1 mg/day at week 1 and 2 mg/day at week 2. If reduction in mood symptoms does not occur, the dose will increase to 3 mg/day and 4 mg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete